Adimune, Inc

Adimune, Inc., based in Mountain View, CA, is pioneering Apoptotic DNA Immunotherapy (ADI), a novel nucleic acid-based technology designed to promote immune tolerance specifically for organ transplantation and autoimmune diseases. By mimicking the body's natural process of apoptosis, ADI selectively suppresses only the immune cells involved in organ rejection, potentially reducing the need for broad immunosuppression and its associated side effects.

The company aims to address significant challenges in organ transplantation, such as chronic rejection and the presence of preformed antibodies, which can complicate the transplant process. Through preclinical studies, Adimune has demonstrated that ADI may prolong graft survival and retrain the immune system to accept transplanted tissues more readily, offering hope for improved outcomes for patients on transplant waiting lists.

Generated from the website